A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis.
This study was designed to compare the efficacy of ciprofloxacin plus rifampin (CR) and ciprofloxacin plus doxycycline (CD) versus doxycycline plus rifampin (DR) in the treatment of brucellosis. A total of 178 patients with brucellosis who were referred to the Sina Hospital, Hamedan, Iran, were included. The responses to therapy were observed in 166 cases (93.7%) - 59 were in the DR group, 59 in the CR group and 48 in the CD group. No significant differences in the therapeutic responses were observed (P = 0.09). Relapse was observed in 11.7% (DR 7.7%, CR 8.3% and CD 17.5%) after a six-month follow-up. No significant differences were also observed in relapse rates among the three groups (P = 0.35). We concluded that DR is still the first choice regimen and CR or CD may be used as alternatives for treatment of brucellosis in adults.
Keramat
Fariba
F
Department of Infectious Diseases, University of Medical Sciences, Hamedan, Iran.
Ranjbar
Mitra
M
Mamani
Mojgan
M
Hashemi
Seyyed Hamid
SH
Zeraati
Fatemeh
F
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002006:Brucellosis / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use
D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D004318:Doxycycline; D012293:Rifampin